Wir sind mit live! Mehr erfahren

BillionToOne Inc

BLLN

Börsenwert 4,63 Mrd. $

98,12 USD

-4,61

4,49 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

98,12

0,00

0 %

1 Tag

-4,49 %

5 Tage

0,52 %

1 Monat

-5,3 %

3 Monate

-23,45 %

6 Monate

24,49 %

Seit Jahresbeginn

9,89 %

1 Jahr

-9,93 %

5 Jahre

-9,93 %

10 Jahre

-9,93 %

Profil: BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Mitarbeiter: 713

Gesundheitswesen Diagnostik & Research

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 22,2 %

Neutral 66,7 %

Negativ 11,1 %

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026

MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026

BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP Credentials

BillionToOne a molecular diagnostic company from California, has experienced quite a topsy-turvey journey since its debut in November last year. BLLN is set to hold on to a consistently high GMS of 70%, which reflects the capabilities of its unique QCT technology that underpins its oncology and prenatal diagnostics product suite. BLLN trades at a slight EV/sales discount to peers but offers best-in-class forward topline growth of 38% p.a., far outpacing the industry average of 22%.

BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP Credentials

BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response

BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to curb excessive Medicare payments and save taxpayers an estimated $1 billion annually.

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

The Motley Fool

BillionToOne SVP Sells 1,416 Shares

The transaction involved 1,416 shares at a weighted average price of $97.54 per share, totaling $138,116 on Sept. 9, 2026. The sale involved shares equal to 5% of the direct equity position held before the transaction.

BillionToOne SVP Sells 1,416 Shares

The Motley Fool

BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million

The transaction involved 30,331 shares executed at a weighted average price of $99.91 per share on September 14, 2026. The shares traded in this filing represented 100% of the insider's directly-held equity stake, and a portion belonging to his spouse.

BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million

BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference.

BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin

New add-on test from a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genes MENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar Origin™, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select® panel from 84 to 102 genes to cover genes that are included in recent and upcoming FDA approvals.

BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin

The Motley Fool

BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million

The transaction involved 10,000 shares at a weighted-average price of $100.00 per share, totaling $1.0 million on the August 25, 2026 transaction date. Following the disposal, the insider holds a direct position of 1,000 shares, which represents approximately 0.0022% of the company's total shares outstanding.

BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results MENLO PARK, Calif., Aug. 18, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population in The Green Journal.

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt